Pre-eclampsia following chemotherapy for breast cancer during pregnancy: case report and review of the literature

Skatulla, L. Massey; Loibl, Sibylle; Schauf, B.; Müller, Thomas

doi:10.1007/s00404-012-2257-y

Cited by 10 publications

(4 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only one major malformation (i.e., pyloric stenosis) was described with the use of docetaxel administered in the second and third trimester [57]. A total of four pregnancies in patients exposed to docetaxel experienced reduction in amniotic fluid: however, trastuzumab was co-administered in two of them [58,59] and the third pregnancy was complicated by placental insufficiency [60]. A high rate of small for gestational age birth weights has been observed in children exposed to docetaxel [28].…”

Section: Docetaxelmentioning

confidence: 97%

Exploring the safety of chemotherapy for treating breast cancer during pregnancy

Lambertini

Kamal

Peccatori

et al. 2015

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

The rule of thumb of chemotherapy - avoiding first trimester exposure and starting therapy in the second trimester - can be considered applicable for classic agents that are used in managing pregnant breast cancer patients. Anthracycline-based regimens are considered the standard of care in managing BCP. Recently, a growing amount of data suggests the safety of taxanes during pregnancy. Pregnancy in cancer patients should be considered as "high risk": once the systemic treatment is initiated, regular fetal monitoring is highly recommended. Emerging data are available on the relative long-term safety secondary to anthracycline exposure during pregnancy. A continued monitoring of the health of individuals with prenatal exposure to chemotherapy into adulthood is recommended for the possible occurrence of long-term side effects.

show abstract

Section: Docetaxelmentioning

confidence: 97%

Exploring the safety of chemotherapy for treating breast cancer during pregnancy

Lambertini

Kamal

Peccatori

et al. 2015

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

show abstract

“…19 Oxidative stress, which is one of the proposed pathophysiological mechanism of preeclampsia, can also be induced by cytotoxic agents. 20 However, the frequency of pre-eclampsia did not increase when chemotherapy was given during pregnancy. The seemingly high rate of caesarean sections might be explained by the number of preterm deliveries and the recommendation to deliver before the 35th week of gestation, as per guidelines in some countries (eg, Germany).…”

Section: Discussionmentioning

confidence: 95%

First trimester placental growth factor and soluble fms-like tyrosine kinase 1 are significantly related to PAPP-A levels

Gruson

Yuemo

Classen

et al. 2012

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

"First trimester placental growth factor and soluble fms-like tyrosine kinase 1 are significantly related to PAPP-A levels" Sibylle Loibl, Sileny N Han, Gunter von Minckwitz, Marijke Bontenbal, Alistair Ring, Jerzy Giermek, Tanja Fehm, Kristel Van Calsteren, Sabine C Linn, Bettina Schlehe, Mina Mhallem Gziri, Pieter J Westenend, Volkmar Müller, Liesbeth Heyns, Brigitte Rack, Ben Van Calster, Nadia Harbeck, Miriam Lenhard, Michael J Halaska, Manfred Kaufmann, Valentina Nekljudova, Frederic Amant SummaryBackground Little is known about the treatment of breast cancer during pregnancy. We aimed to determine whether treatment for breast cancer during pregnancy is safe for both mother and child.

show abstract

“…Regarding the pre-eclampsia, development of this disease was expected in front of many risk factors as its age, the medically assisted reproduction, and the triple gestation [59]. The lack of the pre-eclampsia prevalence increase in case of chemotherapy is highlighted, int an section for a HELLP syndrome at 36 WA but in this patient, pre-eclampsia appears after the 2 cycles of chemotherapy [60]. In addition, Del Gobbo et repercussions in these 23 cases [62].…”

Section: Pre-eclampsiamentioning

confidence: 86%

Systematic Review Concerning the Care of Breast Cancer during Pregnancy with a Case Report of Breast Cancer during Triple Gestation

2023

Ann Case Report

View full text Add to dashboard Cite

Introduction:Cancer affects 1 woman over 1000 during the gestation of which the most common is the breast cancer. Its management is not yet well defined. The study aim is to carry out a systematic review to help achieve the most optimal management. This literature review will be accompanied by a case report concerning a pregnant with a triple fetus complicated by pre-eclampsia and breast cancer at 28 weeks. Methods:We performed a systematic review. The potentially eligible studies were identified by searching the United States National Library of Medicine (PubMed) electronic database, from January 2001 through December 2020, using combinations of the following keywords: (breast cancer) AND (pregnancy) more or less (pre-eclampsia). For pre-eclampsia, the research spanned from January 2010 to December 2020. The Preferred Reporting Items for Systematic review and Meta-Analysis (PRISMA) were used. We examined the retrieved articles and discarded duplicated ones. We also excluded unrelated studies through careful browsing of titles and abstracts of all retrieved publications; studies with an inadequate design, case reports with a low number of participants, and publications in languages other than English were removed.Results: 5018 articles were found concerning breast cancer during pregnancy and 43 on pre-eclampsia and breast cancer, only 54 were kept. Conclusion:Diagnostic and extension assessment of breast cancer during pregnancy is like without pregnancy, the treatment is modulated according to gestational age. The surgery is possible during all trimester. Chemotherapy is prohibited during the first trimester. The target therapy and hormonotherapy are not possible during the pregnancy.

show abstract

Pre-eclampsia following chemotherapy for breast cancer during pregnancy: case report and review of the literature

Cited by 10 publications

References 50 publications

Exploring the safety of chemotherapy for treating breast cancer during pregnancy

Exploring the safety of chemotherapy for treating breast cancer during pregnancy

First trimester placental growth factor and soluble fms-like tyrosine kinase 1 are significantly related to PAPP-A levels

Systematic Review Concerning the Care of Breast Cancer during Pregnancy with a Case Report of Breast Cancer during Triple Gestation

Contact Info

Product

Resources

About